M&A Deal Summary

Precigen Acquires Agarigen

On February 1, 2011, Precigen acquired life science company Agarigen

Acquisition Highlights
  • This is Precigen’s 1st transaction in the Life Science sector.
  • This is Precigen’s 1st transaction in the United States.
  • This is Precigen’s 1st transaction in North Carolina.

M&A Deal Summary
Date 2011-02-01
Target Agarigen
Sector Life Science
Buyer(s) Precigen
Deal Type Add-on Acquisition

Target

Agarigen

Research Triangle Park, North Carolina, United States
Agarigen, Inc. is a developer of a novel, mushroom-based expression platform for the rapid, high yield production of recombinant proteins.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Precigen

Germantown, Maryland, United States
Category Company
Founded 1998
Sector Life Science
Employees202
Revenue 6M USD (2023)
DESCRIPTION

Precigen provides biologically based products and processes that improve the quality of life and health of the planet. The science underlying these products is known as synthetic biology – an engineered approach to the field of biology. Precigen was founded in 1998 and is based in Germantown, Maryland.

DEAL STATS #
Overall 1 of 10
Sector (Life Science) 1 of 9
Type (Add-on Acquisition) 1 of 7
State (North Carolina) 1 of 1
Country (United States) 1 of 6
Year (2011) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-03-07 Medistem

San Diego, California, United States

Medistem, Inc. is a pioneer in the development of Endometrial Regenerative Cells ("ERC" or "ERCs"), universal donor adult-derived stem cells with properties uniquely suited for therapeutic use with Intrexon's existing suite of synthetic biology technologies.

Buy $26M
Mergr

Product

Company

Legal